Low Testosterone Levels Linked to Increased Cancer Mortality Risk

Understanding the Link Between Testosterone and Cancer

Recent research indicates that men with low testosterone levels have an 18% elevated risk of dying from cancer, although this relationship varies by cancer type. Notably, testosterone levels showed no correlation with prostate cancer risk, which was more linked to lower levels of sex hormone-binding globulin (SHBG) and luteinizing hormone.

Research Details and Methodology

Led by Professor Bu Yeap from The University of Western Australia, the Androgens In Men Study (AIMS) investigated the impact of sex hormones on cancer susceptibility. Published in The Lancet Healthy Longevity, the study analyzed data from over 26,000 men participating in multiple long-term studies across Australia, the US, and Europe.

By examining blood samples taken in earlier years, researchers evaluated hormone levels, including testosterone and SHBG, against subsequent cancer diagnoses and deaths. This comprehensive approach allowed the team to ascertain the potential links between these hormone levels and future cancer outcomes.

Key Findings on Hormone Levels

The analysis revealed that men classified in the lowest fifth for testosterone levels faced a heightened risk of cancer-related death, a finding that persisted even when adjusted for age and other health variables. Professor Yeap highlighted that testosterone levels below 8.6 nanomoles per liter (nmol/L) indicated a concerning increase in cancer risk. This range is indicative of healthy testosterone concentrations in younger men, which naturally decline with age.

Factors such as body mass index, activity levels, and certain medical conditions like diabetes can influence testosterone levels. The study suggests that monitoring these levels could aid in identifying men at increased risk of adverse health outcomes, particularly concerning cancer.

Prostate Cancer Insights

A surprising aspect of the findings was the lack of association between testosterone levels and prostate cancer risk. Given that reducing testosterone is a common treatment for prostate cancer, the discovery raises important questions about hormone levels and cancer development. Professor Yeap pointed out that while testosterone did not correlate with prostate cancer risk, low levels of SHBG and luteinizing hormone did show a relationship with an increased risk of developing this specific cancer.

Implications for Treatment and Health Monitoring

Despite the link between low testosterone and increased cancer mortality, Professor Yeap cautioned against automatically assuming that testosterone supplementation could mitigate cancer risk. Current findings do not support the notion that increasing testosterone will lower cancer risk for men already identified as having low levels.

Instead, these findings could serve as a prompting for broader health assessments. Men with low testosterone should consider consulting a physician for comprehensive checkups, as low hormone levels may indicate other underlying health issues or risk factors. Professor Yeap encourages men to adopt healthier lifestyle choices and engage in regular health screenings as proactive measures.

“It could be a wake-up call for men to engage in healthier lifestyles and regular health checkups,” Professor Yeap stated.